Statins Provide a Boost for Kidney Cancer Survival

Scott Eggener, MD

Scott Eggener, MD

Statins, drugs commonly taken for high cholesterol, may have an added benefit for patients with a type of kidney cancer called renal cell carcinoma. A new study by Dr. Scott Eggener, associate professor of surgery, of more than 900 patients with renal cell carcinoma showed that those who were taking statins had a higher rate of survival than those who weren’t. The study was covered today by US News & World Report’s HealthDay:

Statins — drugs such as Crestor, Lipitor, Pravachol and Zocor — have anti-inflammatory and cell self-destruction properties, and previous research has shown that these drugs may lower the risk of developing some types of cancer. The new research, presented Tuesday at the annual meeting of the American Urological Association in San Diego, suggests that the drugs might fight kidney cancer.

“Given that one in four Americans over 45 years of age take a statin and renal cell carcinoma occurs most often in men ages 50 to 70, it may be prudent to prospectively evaluate if statins protect against [cancer] progression,” study author Dr. Scott Eggener, an associate professor of urologic oncology at the University of Chicago, said in a meeting press release.

Dr. Eggener was recently featured in Science Life for his work on a clinical trial of “focal therapy” for prostate cancer that uses a precisely targeted laser to burn away cancer cells instead of using more aggressive invasive surgery.

About Matt Wood (531 Articles)
Matt Wood is a senior science writer and manager of communications at the University of Chicago Medicine & Biological Sciences Division.
%d bloggers like this: